Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
CardiovascularINTRAVENOUSGeneric

PRIMAXIN

CILASTATIN SODIUM; IMIPENEM

Standard Dose
EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview PRIMAXIN is listed in Drugs@FDA under application 050587 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient CILASTATIN SODIUM; IMIPENEM Form and strength POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor MERCK Submission history Latest submission status date: 2022-01-30 00:00:00.

Structured Monograph

Clinical summary

Approval overview PRIMAXIN is listed in Drugs@FDA under application 050587 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient CILASTATIN SODIUM; IMIPENEM Form and strength POWDER;INTRAVENOUS - EQ 250MG BASE/VIAL;250MG/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor MERCK Submission history Latest submission status date: 2022-01-30 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.